Comparison of the diagnostic performance of contrast-enhanced ultrasound and high-resolution magnetic resonance imaging in the evaluation of histologically defined vulnerable carotid plaque: a systematic review and meta-analysis
Chao Hou1,2 , Ji-Qing Xuan1, Li Zhao1, Ming-Xing Li1, Wen He2#, Hui Liu1#
Contributions: (I) Conception and design: C Hou, W He, H Liu; (II) Administrative support: W He, H Liu; (III) Provision of study materials or patients: C Hou, JQ Xuan, L Zhao, MX Li; (IV) Collection and assembly of data: JQ Xuan, L Zhao; (V) Data analysis and interpretation: MX Li, W He; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
#These authors contributed equally to this work as co-last authors.
Background: Vulnerable carotid plaque is closely associated with ischemic stroke. Contrast-enhanced ultrasound (CEUS) and high-resolution magnetic resonance imaging (HR-MRI) are two imaging modalities capable of assessing the vulnerability of carotid plaques. This systematic review aimed to compare the diagnostic performance of CEUS and HR-MRI in the evaluation of histologically defined vulnerable carotid plaques.
Methods: A systematic literature search with predefined search terms was performed on PubMed, the Cochrane library, Embase, and Web of Science from January 2001 to December 2023. Studies that evaluated the diagnostic accuracy of vulnerable carotid plaques confirmed by histology with CEUS and/or HR-MRI were included. The pooled values were calculated using a random-effects meta-analysis to determine diagnostic power.
Results: This analysis included a total of 839 patients from 20 studies comprising 1,357 HR-MRI plaques and CEUS 504 plaques. With the reference to histological results, all nine CEUS studies focused on the detection of intraplaque neovascularization (IPN), and three studies also examined morphological changes or ulcerated plaques; meanwhile, among the HR-MRI studies, seven predominantly focused on identifying intraplaque hemorrhage (IPH) and three mainly examined lipid-rich necrotic cores (LRNCs). The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the area under the curve (AUC) for CEUS studies were 0.85 [95% confidence interval (CI): 0.81–0.89], 0.76 (95% CI: 0.69–0.83), 3.41 (95% CI: 1.68–6.94), 0.14 (95% CI: 0.05–0.38), 27.68 (95% CI: 5.78–132.62), and 0.89 [standard error (SE) 0.06], respectively; for HR-MRI, these values were 0.88 (95% CI: 0.85–0.90), 0.89 (95% CI: 0.86–0.92), 7.49 (95% CI: 3.28–17.09), 0.17 (95% CI: 0.12–0.24), 49.13 (95% CI: 23.87–101.11), and 0.94 (SE 0.01), respectively. The difference in AUC between the two modalities was not statistically significant (Z=0.82; P=0.68).
Conclusions: CEUS and HR-MRI are valuable noninvasive diagnostic tools for identifying histologically confirmed vulnerable carotid plaques and demonstrate similar diagnostic performance. CEUS is more capable of detecting IPN and morphological changes, while HR-MRI is more suited to classifying IPH and LRNCs.
Keywords: Ultrasonography; microbubble; magnetic resonance imaging (MRI); carotid artery; plaque
Submitted Mar 17, 2024. Accepted for publication Jul 05, 2024. Published online Jul 26, 2024.
doi: 10.21037/qims-24-540
IntroductionOther Section
Stroke as a significant threat to the health of individuals worldwide, ranks as the second leading cause of death globally, following ischemic heart disease (1). Ischemic stroke, which constitutes 62.4% of all stroke cases (2), is imposing a growing burden on young adults in regions with low scores sociodemographic indices such as North Africa, the Middle East, and Southeast Asia (3). Carotid atherosclerosis is recognized as a contributing factor to ischemic stroke, and the risk of stroke caused by carotid artery stenosis increases with advancing age (4). Specifically, vulnerable plaques, characterized by thin or ruptured fibrous caps, intraplaque neovascularization (IPN), intraplaque hemorrhage (IPH), lipid-rich necrotic cores (LRNCs), ulceration, or inflammation, are associated with an increased risk of distal cerebral artery emboli blockage (5), which can lead to ischemic stroke. Both IPN and IPH have been identified as independent predictors of stroke recurrence in ischemic stroke survivors (6,7). Therefore, the early detection and treatment of vulnerable plaques could prove to be an effective strategy in preventing both the initial occurrence and subsequent recurrence of stroke.
Contrast-enhanced ultrasound (CEUS) and high-resolution magnetic resonance imaging (HR-MRI) are two commonly used tools to assess plaque vulnerability. CEUS has high sensitivity and specificity in identifying IPN and ulceration and in outlining luminal morphology (8,9). Meanwhile, HR-MRI is capable of detecting IPH and LRNCs (10). However, despite their respective strengths, CEUS and HR-MRI are also associated with distinct disadvantages. For instance, HR-MRI provides high soft-tissue and spatial resolution but is limited by its high cost, lengthy examination time, tendency to induce claustrophobia, and susceptibility to potential interference from metal objects in the body. As it pertains to CEUS, in which the contrast agent can be eliminated through respiration with minimal anaphylactoid reactions, its resolution may be affected by pseudoenhancement, obesity, postural restrictions, and subcutaneous gas. Therefore, it is necessary to determine whether these two modalities can be used complementarily to identify vulnerable plaques, which can significantly impact clinical and personal intervention.
Although several meta-analyses have assessed the diagnostic performance of HR-MRI and CEUS individually and have demonstrated their efficacy in identifying vulnerable plaques (11,12), only one study has directly compared these modalities’ ability to detect unstable plaques (13). This meta-analysis, conducted by Li et al. (13), was based on a limited sample size of nine original studies published as of December 2021 and thus does not completely represent the entire body of research in this field. Plaque ulceration is one feature of susceptible plaque, but Li et al. did not include histologically proven ulcerated plaques in their analysis. Furthermore, they did not investigate the differences in the specific components of plaques which the two imaging tools focus on for detection. Therefore, this study aimed to systematically compare the diagnostic accuracy of CEUS and HR-MRI in evaluating carotid plaque vulnerability as defined by histology via a meta-analysis and to determine whether CEUS can serve as an alternative modality to HR-MRI for plaque vulnerability assessment. We present this article in accordance with the PRISMA-DTA reporting checklist (14) (available at https://qims.amegroups.com/article/view/10.21037/qims-24-540/rc).
MethodsOther Section
Data sources and search strategy
We systematically searched PubMed, the Cochrane library, Embase, and Web of Science for articles published in the English or Chinese language with an English-language abstract from January 2001 to December 2023. The search strategy is shown in Table S1. The protocol of this systematic review has been registered in PROSPERO (International Prospective Register of Systematic Reviews; registration No. CRD42023494214).
Inclusion and exclusion criteria
We aimed to include all original studies that reported the diagnostic performance of CEUS and HR-MRI in the evaluation of carotid plaques. Two reviewers (J.Q.X. and L.Z.) independently assessed the titles and abstracts of the articles we searched. The inclusion criteria by category were as follows: (I) participants—patients with carotid plaque; (II) intervention and control—CEUS and/or HR-MRI examinations; (III) outcomes—diagnostic accuracy for identifying vulnerable plaques; (IV) study design—both observational (retrospective or prospective) and clinical trials; and (V) reference standard—histologically defined vulnerable plaques with one of the conditions of IPH, IPN, LRNC, thin or ruptured fibrous cap, ulceration, or inflammatory infiltrate being present. Meanwhile, the exclusion criteria were as follows: (I) duplicate patients or data; (II) animal studies; (III) insufficient information to create a 2×2 diagnostic table; (IV) case reports, narrative reviews, letters, editorial comments, and conference abstracts; and (V) a focus on cerebral vascular events caused by other diseases such as carotid dissection, vasculitis, or atrial fibrillation.
Data extraction and quality assessment
The variables extracted include the name of the first author; publication year; country; number of patients; gender; age; prevalence of diabetes, hypertension, smoking, dyslipidemia, and cardiovascular disease; study design; focused plaque composition based on histological results; patient type; and the technical details of CEUS and HR-MRI. To assess the risk of bias in the literature, we searched for the Journal Citation Reports (JCR) of journals in the year of publication of each study. We extracted or calculated the absolute number of true positives (TPs), false positives (FPs), false negatives (FNs), and true negatives (TNs) from each study even when multiple data sets were present. Two independent investigators (M.X.L. and W.H.) assessed the risk of bias and applicability concerns using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool (15). Any disagreements were resolved by consensus.
Statistical analysis
This analysis was conducted using Meta-Disc version 1.4 (Ramón y Cajal Hospital, Madrid, Spain). Two-by-two tables were constructed for each study to calculate the sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR−), diagnostic odds ratio (DOR), and their respective 95% confidence intervals (CIs). Moses linear models were used to generate a summary receiver operating characteristic (SROC) curve and calculate the area under the curve (AUC).
A Spearman correlation index between the logarithm of sensitivity and the logarithm of 1-specificity was applied to determine the presence of a threshold effect. A correlation coefficient greater than a certain value and a significance level of P<0.05 were indicative of a threshold effect; otherwise, a threshold effect was considered to be absent. Heterogeneity was assessed using either the chi-square test or Cochrane Q test. The I2 statistic was employed to estimate the percentage of variability in results among studies that could be attributed to true differences in patients, tests, outcomes, and design rather than random chance. Values of 25%, 50%, and 75% were considered to represent low, moderate, and high inconsistency, respectively (16). The meta-analysis was carried out using a random-effects model in cases of moderate or high heterogeneity; otherwise, a fixed-effects model was used.
Subgroup analysis and sensitivity analysis were conducted to investigate the sources of heterogeneity. Subgroups were categorized by country, study design, sample sizes, plaque components, mechanical indexes (MIs), magnetic field strength, and journal JCR region. Sensitivity analysis involved the systematic one-by-one removal of studies. Deeks funnel plot of CEUS and MRI was generated using Stata version 17.0 (StataCorp, College Station, TX, USA) to assess publication bias. An asymmetry curve with P≥0.05 indicated a lack of significant publication bias. The risk of bias and applicability were assessed using RevMan version 5.3 (Informatics and Knowledge Management Department, Cochrane, London, UK).
ResultsOther Section
Literature search
The systematic research retrieved 2,652 studies, 1,700 of which were found to be duplicated. Following the retrieval and evaluation of titles and abstracts, 850 studies were excluded. Subsequently, 102 studies were deemed eligible and for full-text review, with 20 ultimately meeting the inclusion criteria for this meta-analysis. Specifically, 7 studies focused on CEUS (17-23), 11 on HR-MRI (10,24-33), and 2 studies covered both modalities (34,35). A flowchart illustrating the research and selection process is presented in Figure 1.
Figure 1 Flowchart of study selection using the PRISMA guidelines. CEUS, contrast-enhanced ultrasound; HR-MRI, high-resolution magnetic resonance imaging; PRISMA, Preferred Reporting Items for Systematic Review and Meta-Analysis.
Table 1 summarizes the clinical details of the 20 articles. A total of 839 patients were included; 3 studies did not report the gender components (17,21,29) or age distribution (17,29,30), respectively; and the remaining study population was composed 78.7% (528/671) of men and had a mean age of 70.15±4.24 years (n=687). The majority of studies were from China (30%), followed by Italy (25%), Japan (15%), and the United States (10%), while Switzerland, the United Kingdom, the Netherlands, and Germany each accounted for only 5% of the included literature. The population size varied from 11 to 101. Twelve studies (10,17,19,20,23,24,26-30,32) were published in JCR region 1 journals and six in JCR region 2 journals (18,22,25,31,33,34). The values of TPs, FPs, FNs, and TNs are available in Table 1.
Table 1
The clinical characteristics of the included studies
First author (year) | Country | Age (years, mean ± SD) | Population size (men, %) | Patient type | TP (n) | FP (n) | FN (n) | TN (n) | DM (n) | HPN (n) | Smoking (n) | Dyslipidemia (n) | Symptomatic (n) | JCR region |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresilli D (2022) (17) | Italy | NA | 101 (NA) | Symptomatic stenosis ≥50% and asymptomatic stenosis ≥60% | 64 | 1 | 7 | 29 | NA | NA | NA | NA | NA | 1 |
Huang S (2021) (18) | China | 68.3±9.5 | 38 (34, 89.5%) | Carotid stenosis ≥50% | 25 | 2 | 3 | 8 | 15 | 26 | 37 | 38 | 37 | 2 |
D’Oria (2018) (19) | Italy | 72.8±6.6 | 58 (33, 56.9%) | Asymptomatic stenosis ≥70% | 12 | 10 | 27 | 9 | 46 | 24 | 27 | 45 | 0 | 1 |
Lyu Q (2021) (20) | China | 67±6.5 | 51 (43, 84.3%) | Symptomatic stenosis ≥50% and asymptomatic stenosis ≥70% | 21 | 2 | 3 | 25 | 28 | 31 | NA | NA | 42 | 1 |
Di Leo (2018) (21) | Italy | 69.8±8.5 | 43 (NA) | CEA | 27 | 5 | 4 | 7 | NA | NA | NA | NA | NA | NA |
Iezzi R (2015) (22) | Italy | 69.9±7.3 | 50 (28, 56.0%) | Carotid stenosis ≥70% | 35 | 5 | 2 | 11 | NA | NA | NA | NA | 18 | 2 |
Uchihara Y (2023) (23) | Japan | 71.7±1.05 | 68 (67, 98.5%) | CEA | 61 | 1 | 1 | 5 | 21 | 58 | 12 | 50 | 47 | 1 |
Chai JT (2017) (10) | China | 67.5 | 26 (19, 73.1%) | 50–90% carotid stenosis | 17 | 1 | 0 | 8 | 8 | 23 | 11 | 19 | 15 | 1 |
Hideki O (2010) (24) | United States | 67.7±10.8 | 20 (16, 80.0%) | Carotid stenosis >80% and symptomatic stenosis >70% | 40 | 4 | 10 | 130 | 5 | 14 | 11 | 16 | NA | 1 |
Narumi S (2015) (25) | Japan | 70.4 | 34 (31, 91.2%) | Substantial stenosis | 20 | 0 | 0 | 14 | NA | NA | NA | NA | 26 | 2 |
Puppini G (2006) (26) | Italy | 72.5 | 19 (13, 68.4%) | Symptomatic carotid stenosis ≥70% | 45 | 0 | 3 | 8 | NA | NA | NA | NA | 19 | 1 |
Moody AR (2003) (27) | United Kingdom | 69 | 63 (33, 52.4%) | Carotid stenosis >70% | 37 | 3 | 7 | 16 | NA | NA | NA | NA | 63 | 1 |
Cai JM (2002) (28) | China | 70 | 60 (54, 90.0%) | CEA | 75 | 14 | 17 | 146 | NA | NA | NA | NA | NA | 1 |
Kampschulte A (2004) (29) | Germany | NA | 24 (NA) | CEA | 134 | 9 | 6 | 41 | NA | NA | NA | NA | NA | 1 |
Chu B (2004) (30) | United States | NA | 27 (21, 77.8%) | CEA | 130 | 11 | 15 | 33 | NA | NA | NA | NA | 13 | 1 |
Qiao Y (2011) (31) | China | 72 | 15 (13, 86.7%) | Carotid stenosis ≥58% | 55 | 1 | 8 | 80 | NA | NA | NA | NA | 8 | 2 |
Cappendijk VC (2004) (32) | The Netherlands | 68±4 | 11 (7, 63.6%) | Symptomatic carotid stenosis ≥70% | 35 | 4 | 8 | 47 | NA | NA | NA | NA | 11 | 1 |
Tapis P (2020) (33) | Switzerland | 71.5±8.68 | 36 (29, 80.6%) | Carotid stenosis ≥70% | 19 | 0 | 13 | 4 | 6 | 23 | 12 | 28 | 25 | 2 |
Motoyama R (2019) (34) | Japan | 71.5±6.5 | 70 (68, 97.1%) | Carotid plaque | 44a/43b | 8a/16b | 4a/5b | 14a/6b | 21 | 60 | 12 | 52 | 48 | 2 |
Zhao KQ (2018) (35) | China | 66.5 | 25 CEUS (19, 76%), 19 HR-MRI (19, 100%) | Symptomatic stenosis ≥50% and asymptomatic stenosis ≥70% | 15a/10b | 2a/2b | 1a/2b | 7a/5b | 18 | 20 | NA | NA | NA | NA |
a value for contrast-enhanced ultrasound study; b value for high-resolution magnetic resonance imaging study. SD, standard deviation; TP, true positive; FP, false positive; FN, false negative; TN, true negative; DM, diabetes mellitus; HPN, hypertension; JCR, Journal Citation Reports; NA, not available; CEA, carotid endarterectomy; CEUS, contrast-enhanced ultrasound; HR-MRI, high-resolution magnetic resonance imaging.
Risk of bias and applicability
The results and details of the QUADAS-2 assessment for the 20 studies are summarized in Figure 2A,2B and Table S2. Although the overall quality of the 19 studies was moderate, the QUADAS-2 tool identified some potential sources of bias. Flow and timing emerged as the primary source of bias, followed by patient selection. In the flow and timing domain, the interval between the index test and reference test was unclear in 60.0% of the studies (19-22,24,25,27,28,31,33,35,36), and 20.0% of studies did not include all patients in the final analysis (23,29,31,33). Concerning the patient selection domain, 60.0% of studies did not clearly describe the inclusion and exclusion criteria (10,19,21,25-27,29-34), and participant enrollment was unclear in nine studies (10,18,19,26,29,30,32,33,35). Additionally, four studies (18,21,26,35) did not report whether the assessment was blinded or not, and three studies employed single blinding (17,22,25).
Figure 2 Risk of bias and applicability concerns of (A) each included study and (B) the overall judgment assessed using the revised Quality Assessment of Diagnostic Accuracy Studies 2.
Synthesis of results
Threshold effects
The Spearman correlation coefficient of CEUS was −0.350 (P=0.356), while that of HR-MRI was 0.121 (P=0.694), indicating no threshold effects in the two diagnostic tests. The Cochran Q, I2, and P values of the DOR for CEUS were 56.41, 85.8%, and <0.001, while those for HR-MRI were 34.19, 64.9%, and <0.001, respectively, representing high and moderate heterogeneity among the CEUS and HR-MRI studies, respectively. Therefore, a random-effects model was applied for the corresponding meta-analysis.
Diagnostic performances of CEUS and HR-MRI
All 20 studies used histology as the reference standard, and details of the methodology of each study are provided in Table 2. According to the histological findings, all CEUS studies focused on the detection of IPN, while three studies (17,18,20) also examined morphological changes or ulcerated plaques. The pooled sensitivity, specificity, LR+, LR−, DOR, and AUC were 0.85 (95% CI: 0.81–0.89), 0.76 (95% CI: 0.69–0.83), 3.41 (95% CI: 1.68–6.94), 0.14 (95% CI: 0.05–0.38), 27.68 (95% CI: 5.78–132.62), and 0.89 [standard error (SE) 0.06], respectively. In terms of HR–MRI, seven studies focused on identifying IPH (24,25,29-32,34), three studies on LRNC (10,26,33), and the remaining studies on complex components (27,28,35) (Table 2). The pooled sensitivity, specificity, LR+, LR−, DOR, and AUC were 0.88 (95% CI: 0.85–0.90), 0.89 (95% CI: 0.86–0.92), 7.49 (95% CI: 3.28–17.09), 0.17 (95% CI: 0.12–0.24), 49.13 (95% CI: 23.87–101.11), and 0.94 (SE 0.01), respectively (Figures 3,4). A Z test indicated that the pooled AUC differences between CEUS and HR-MRI were not statistically significant (Z=0.82; P=0.68).
Table 2
Summary of the methodological difference in studies
First author (year) | Research type | Plaque component confirmed by | CEUS | HR-MRI | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Machine/probe | MI | Contrast agent | Analysis method | Device manufacture | Magnetic field strength | Sequence | ||||
Fresilli D (2022) (17) | R | IPN and ulceration | Samsung, RS80 and 85 Prestige, L3–L12 | 0.06–0.08 | SonoVue | Qualitative G1–3 | – | – | – | |
Huang S (2021) (18) | R | IPN and ulceration | Supersonic AixPlorer, 10–2L | NA | SonoVue | Qualitative G1–4 | – | – | – | |
D’Oria (2018) (19) | P | IPN | MyLab, Esaote, 9L4 | 0.13 | SonoVue | Quantitative/qualitative G0–3 | – | – | – | |
Lyu Q (2021) (20) | P | IPN and morphology | Phillips iU-Elite, L9–3 | <0.1 | SonoVue | Qualitative G1–3 | – | – | – | |
Di Leo (2018) (21) | R | IPN | Toshiba Aplio 500 | 0.05–0.07 | SonoVue | Quantitative/qualitative G1–3 | – | – | – | |
Iezzi R (2015) (22) | P | IPN | MyLab, Esaote | 0.13 | SonoVue | Qualitative G1–3 | – | – | – | |
Uchihara Y (2023) (23) | R | IPN | GE LOGIQ E9 | 0.2–0.3 | Sonazoid | Qualitative G0–3 | – | – | – | |
Chai JT (2017) (10) | P | LRNC | – | – | – | – | Siemens | 3.0 T | TOF, 2D T2 mapping | |
Hideki O (2010) (24) | P | IPH | – | – | – | – | Philips/GE | 3.0 T | 3D MPRAGE, 3D TOF, 2D T1FSE | |
Narumi S (2015) (25) | P | IPH | – | – | – | – | GE | 1.5 T | 3D-FSE T1WI and 2D spin-echo T1WI | |
Puppini G (2006) (26) | R | LRNC | – | – | – | – | Siemens | 1.5 T | 3D TOF, T1WI, T2WI, PDWI | |
Moody AR (2003) (27) | P | Complex | – | – | – | – | Siemens | 1.5 T | MRDTI | |
Cai JM (2002) (28) | P | IPH, LRNC | – | – | – | – | GE | 1.5 T | TOF, T1WI, T2WI, PDWI | |
Kampschulte A (2004) (29) | P | IPH | – | – | – | – | GE | 1.5 T | TOF, T1WI, T2WI, PDWI | |
Chu B (2004) (30) | P | IPH | – | – | – | – | GE | 1.5 T | 3D TOF MRA, T1WI, T2WI, PDWI | |
Qiao Y (2011) (31) | R | IPH | – | – | – | – | Philips | 3.0 T | 3D FFE, 3D-TOF MRA | |
Cappendijk VC (2004) (32) | R | IPH | – | – | – | – | Philips | 1.5 T | T1W TFE, T1W TSE | |
Tapis P (2020) (33) | R | LRNC | – | – | – | – | Siemens | 3.0 T | 3D TOF, T1WI, T2WI | |
Motoyama R (2019) (34) | P | IPN/IPH | GE LOGIQ E9, 9L | 0.2–0.3 | Sonazoid | Qualitative G0–G3 | Siemens | 3.0 T | MPRAGE | |
Zhao KQ (2018) (35) | P | IPN/complex | Toshiba Aplio i500, 11L | NA | NA | Qualitative G1–2 | NA | NA | T1WI, T2WI, 3D TOF |
CEUS, contrast-enhanced ultrasound; MI, mechanical index; HR-MRI, high-resolution magnetic resonance imaging; R, retrospective; IPN, intraplaque neovascularization; G, grade; NA, not available; P, prospective; LRNC, lipid-rich necrotic core; TOF, time of flight; 2D, two-dimensional; IPH, intraplaque hemorrhage; 3D, three-dimensional; MPRAGE, magnetization-prepared rapid acquisition with gradient echo; FSE, fast spin echo; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; PDWI, proton density-weight imaging; MRDTI, magnetic resonance direct thrombus imaging; MRA, magnetic resonance angiography; FFE, fast-field echo; TFE, turbo field echo; TSE, turbo spin echo.
Figure 3 Forest plots of (A) sensitivity, (B) specificity, (C) diagnostic odds ratio, and (D) the summary receiver operator characteristic curve of the CEUS studies. In (D), the first and the third blue lines represent the 95% CI of AUC, and the second blue line represents the regression line. OR, odds ratio; CI, confidence interval; SROC, summary receiver operating characteristic; AUC, area under the curve; SE, standard error; CEUS, contrast-enhanced ultrasound.
Figure 4 Forest plots of (A) sensitivity, (B) specificity, (C) diagnostic odds ratio, and (D) the summary receiver operator characteristic curve of the HR-MRI studies. In (D), the first and the third blue lines represent the 95% confidence interval of AUC, and the second blue line represents the regression line. CI, confidence interval; OR, odds ratio; SROC, summary receiver-operating characteristic; AUC, area under the curve; SE, standard error; HR-MRI, high-resolution magnetic resonance imaging.
Subgroup analysis
Subgroup analyses were employed to investigate the sources of heterogeneity for CEUS and HR-MRI in terms of DOR. A statistically significant level of P<0.05 indicated a possible source of heterogeneity. The findings suggested that factors including country, sample size, plaque component, and JCR region may contribute to the observed variability in CEUS and HR-MRI. In addition, the heterogeneity was also influenced by the MI in CEUS and magnetic field strength in MRI (Table 3, Tables S3,S4).
Table 3
Subgroup analysis of the CEUS and HR-MRI studies
Subgroup | CEUS | HR-MRI | |||||
---|---|---|---|---|---|---|---|
Studies (n) | DOR (95% CI) | Heterogeneity, I2 (%) (P) | Studies (n) | DOR (95% CI) | Heterogeneity, I2 (%) (P) | ||
Region | |||||||
Asia | 5 | 41.43 (17.62–97.41) | 0.0 (0.44) | 6 | 54.44 (10.27–288.43) | 79.8 (<0.001) | |
Europe | 4 | 12.57 (0.73–215.56) | 92.1 (<0.001) | 7 | 53.72 (28.90–99.87) | 29.0 (0.20) | |
Study design | |||||||
Prospective | 5 | 15.16 (1.55–148.01) | 89.9 (<0.001) | 10 | 43.12 (19.12–97.25) | 67.5 (0.001) | |
Retrospective | 4 | 57.49 (10.28–321.62) | 63.7 (0.04) | 3 | 81.39 (12.30–538.53) | 61.1 (0.08) | |
Sample size | |||||||
≥50 | 6 | 31.08 (3.18–303.68) | 90.7 (<0.001) | 8 | 45.74 (20.08–104.21) | 74.8 (<0.001) | |
<50 | 3 | 19.29 (6.42–57.97) | 0.0 (0.43) | 5 | 68.08 (12.54–369.51) | 36.0 (0.18) | |
Plaque composition | |||||||
IPN | 6 | 24.85 (2.37–260.85) | 89.4 (<0.001) | 5 | 44.48 (10.86–182.24) | 83.7 (0.0001) | |
Others | 3 | 32.19 (12.98–83.49) | 0.0 (0.44) | 8 | 54.40 (28.21–104.90) | 17.3 (0.29) | |
Mechanical index | |||||||
>0.2 | 4 | 34.10 (13.06–89.04) | 0.0 (0.39) | – | – | ||
≤0.2 | 5 | 18.33 (1.53–219.54) | 91.3 (<0.001) | – | – | ||
Strength field | |||||||
1.5 T | – | – | 7 | 49.24 (28.77–84.26) | 22.5 (0.26) | ||
Others | – | – | 6 | 41.73 (6.76–257.45) | 80.8 (<0.001) | ||
JCR region | |||||||
1 | 4 | 37.19 (0.83–1,668.75) | 93.9 (<0.001) | 8 | 54.16 (33.77–86.87) | 16.3 (0.30) | |
≤2 | 5 | 21.57 (10.01–46.46) | 0.0 (0.72) | 5 | 41.07 (3.62–465.84) | 82.2 (0.0002) |
CEUS, contrast-enhanced ultrasound; HR-MRI, high-resolution magnetic resonance imaging; DOR, diagnostic odds ratio; CI, confidence interval; IPN, intraplaque neovascularization; JCR, Journal Citation Reports.
Sensitivity analysis
The results of the sensitivity analysis indicated that D’Oria et al.’s study (19) may be the primary cause of heterogeneity among the included CEUS studies. After this study was excluded, a fixed-effects model was used to assess the combined values of the remaining CEUS studies. The pooled sensitivity, specificity, LR+, LR−, DOR, and AUC were 0.92 (95% CI: 0.88–0.95), 0.80 (95% CI: 0.72–0.87), 4.00 (95% CI: 2.35–6.81), 0.12 (95% CI: 0.08–0.17), 41.49 (95% CI: 18.47–93.23), and 0.95 (SE 0.02), respectively. The difference in AUC between the remaining CEUS studies and HR-MRI studies was not statistically significant (Z=0.16; P=0.43). The sensitivity analysis for HR-MRI yielded robust results, as the aggregated values remained consistent even after the one-by-one removal of individual studies. Tables 4 and 5 present the findings of the sensitivity analyses conducted for the CEUS and HR-MRI studies.
Table 4
Sensitivity analysis of CEUS studies
Removed study | Sensitivity (95% CI) | Specificity (95% CI) | LR+ (95% CI) | LR− (95% CI) | DOR (95% CI) | AUC (SE) | Heterogeneity, I2 (%) (P) |
---|---|---|---|---|---|---|---|
Fresilli D (17) | 0.84 (0.79–0.88) | 0.71 (0.62–0.79) | 2.82 (1.48–5.37) | 0.15 (0.05–0.45) | 20.93 (4.19–104.53) | 0.80 (0.10) | 85.4 (<0.001) |
Huang S (18) | 0.85 (0.81–0.89) | 0.76 (0.68–0.83) | 3.34 (1.54–7.23) | 0.14 (0.05–0.42) | 27.39 (4.82–155.64) | 0.89 (0.07) | 87.3 (<0.001) |
D’Oria (19) | 0.92 (0.88–0.95) | 0.80 (0.72–0.87) | 4.00 (2.35–6.81) | 0.12 (0.08–0.17) | 41.49 (18.47–93.23) | 0.95 (0.02) | 25.4 (0.23) |
Lyu Q (20) | 0.85 (0.81–0.89) | 0.73 (0.64–0.80) | 2.92 (1.44–5.93) | 0.14 (0.05–0.42) | 24.03 (4.44–130.06) | 0.86 (0.09) | 86.4 (<0.001) |
Di Leo (21) | 0.85 (0.81–0.89) | 0.78 (0.70–0.84) | 3.80 (1.63–8.87) | 0.13 (0.04–0.41) | 32.65 (5.34–199.54) | 0.89 (0.06) | 87.6 (<0.001) |
Iezzi R (22) | 0.84 (0.80–0.88) | 0.77 (0.69–0.84) | 3.59 (1.55–8.33) | 0.15 (0.05–0.43) | 27.22 (4.73–156.75) | 0.89 (0.07) | 87.2 (<0.001) |
Uchihara Y (23) | 0.82 (0.78–0.87) | 0.76 (0.68–0.83) | 3.26 (1.55–6.88) | 0.17 (0.07–0.47) | 21.67 (4.30–109.26) | 0.89 (0.06) | 86.4 (<0.001) |
Motoyama R (34) | 0.84 (0.80–0.88) | 0.78 (0.70–0.85) | 3.76 (1.54–9.15) | 0.14 (0.05–0.43) | 29.87 (4.73–188.67) | 0.90 (0.06) | 87.4 (<0.001) |
Zhao KQ (35) | 0.85 (0.81–0.89) | 0.76 (0.68–0.83) | 3.36 (1.55–7.31) | 0.15 (0.05–0.43) | 25.97 (4.79–140.82) | 0.89 (0.07) | 87.3 (<0.001) |
CEUS, contrast-enhanced ultrasound; CI, confidence interval; LR+, positive likelihood ratio; LR−, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; SE, standard error.
Table 5
Sensitivity analysis of HR-MRI studies
Removed study | Sensitivity (95% CI) | Specificity (95% CI) | LR+ (95% CI) | LR− (95% CI) | DOR (95% CI) | AUC (SE) | Heterogeneity, I2 (%) (P) |
---|---|---|---|---|---|---|---|
Chai JT (10) | 0.87 (0.85–0.90) | 0.89 (0.86–0.92) | 7.60 (3.18–18.13) | 017 (0.12–0.25) | 46.73 (22.27–98.05) | 0.93 (0.01) | 67.0 (<0.001) |
Hideki O (24) | 0.88 (0.85–0.90) | 0.87 (0.84–0.90) | 6.56 (2.87–15.00) | 0.16 (0.11–0.24) | 44.07 (20.53–94.58) | 0.93 (0.01) | 64.2 (0.001) |
Narumi S (25) | 0.87 (0.85–0.90) | 0.89 (0.86–0.91) | 6.99 (3.02–16.14) | 0.17 (0.12–0.25) | 44.88 (21.94–91.83) | 0.93 (0.01) | 65.1 (<0.001) |
Puppini G (26) | 0.87 (0.84–0.89) | 0.89 (0.86–0.91) | 7.19 (3.09–16.70) | 0.18 (0.12–0.26) | 46.18 (22.02–96.83) | 0.93 (0.01) | 66.7 (<0.001) |
Moody AR (27) | 0.88 (0.85–0.90) | 0.89 (0.87–0.92) | 7.78 (3.20–18.89) | 0.16 (0.11–0.24) | 52.41 (23.91–114.89) | 0.94 0.02) | 67.5 (<0.001) |
Cai JM (28) | 0.88 (0.86–0.91) | 0.88 (0.85–0.91) | 7.42 (2.97–18.55) | 0.16 (0.10–0.25) | 51.12 (21.75–120.14) | 0.94 (0.01) | 67.8 (<0.001) |
Kampschulte A (29) | 0.86 (0.83–0.88) | 0.90 (0.87–0.92) | 7.90 (3.07–20.30) | 0.19 (0.14–0.26) | 45.39 (20.74–99.35) | 0.92 (0.01) | 65.2 (<0.001) |
Chu B (30) | 0.87 (0.84–0.90) | 0.90 (0.88–0.93) | 8.29 (3.09–22.24) | 0.17 (0.11–0.25) | 54.30 (23.95–123.10) | 0.94 (0.01) | 66.1 (<0.001) |
Qiao Y (31) | 0.88 (0.85–0.90) | 0.88 (0.85–0.90) | 6.37 (2.86–14.17) | 0.17 (0.12–0.25) | 41.21 (20.47–83.0) | 0.93 (0.01) | 61.3 (0.002) |
Cappendijk VC (32) | 0.88 (0.85–0.90) | 0.89 (0.86–0.91) | 7.28 (3.04–17.45) | 0.16 (0.11–0.24) | 49.59 (22.30–110.24) | 0.94 (0.01) | 67.8 (<0.001) |
Tapis P (33) | 0.89 (0.86–0.91) | 0.89 (0.86–0.92) | 7.59 (3.24–17.79) | 0.15 (0.11–0.20) | 52.21 (24.75–110.15) | 0.94 (0.01) | 67.2 (<0.001) |
Motoyama R (34) | 0.87 (0.85–0.90) | 0.92 (0.89–0.94) | 8.02 (5.00–12.86) | 0.16 (0.11–0.23) | 61.07 (34.56–107.9) | 0.94 0.01) | 38.9 (0.08) |
Zhao KQ (35) | 0.88 (0.85–0.90) | 0.89 (0.87–0.92) | 8.18 (3.39–19.75) | 0.16 (0.11–0.24) | 53.77 (25.37–113.98) | 0.94 (0.01) | 66.6 (<0.001) |
HR-MRI, high-resolution magnetic resonance imaging; CI, confidence interval; LR+, positive likelihood ratio; LR−, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; SE, standard error.
Publication bias
Results of Deeks funnel plots showed no statistically significant publication bias in the CEUS (P=0.85) or HR-MRI studies (P=0.78) (Figure S1A,S1B).
Conflicts of interest, funding source, and role of funding source
None of the studies reported a conflict of interest with the funding source or with the role of the funding source.
DiscussionOther Section
Principal findings
This meta-analysis examined 839 patients across 20 studies comprising 1,357 plaques in HR-MRI and 504 plaques in CEUS to compare the diagnostic ability of these two modalities in evaluating the vulnerability of carotid artery plaques defined by histology. The results demonstrated that both CEUS and HR-MRI provide acceptable diagnostic accuracy, with high AUC values (0.89 vs. 0.94). CEUS demonstrated comparable performance to HR-MRI in detecting unstable carotid atherosclerotic artery plaques. As it pertains to plaque components, CEUS appears to be superior in assessing IPN and morphological changes, while MRI is more suited for assessing IPH and LRNC.
To our knowledge, only one systematic review has compared CEUS and HR-MRI in terms of plaque vulnerability assessment (13). Our review is novel for the following reasons: First, although we used the same search strategy as that of Li et al., we included twice as many articles (with the exception of two recent studies published in 2022–2023), allowing for a more thorough evaluation of the diagnostic performance. Second, due to high and moderate heterogeneity among the CEUS and HR-MRI studies, respectively, we conducted subgroup analyses based on study design, plaque composition, MI, and JCR region (Table 3), which enabled us to determine the source of heterogeneity. Third, we summarized the value of the two imaging methods for identifying distinct plaque components using the pathological findings as a reference.
Diagnostic performance of CEUS
Our meta-analysis revealed that CEUS had a pooled sensitivity of 0.82 (95% CI: 0.78–0.87) and a specificity of 0.76 (95% CI: 0.68–0.83), which is higher than that reported by Li et al. (13) but lower than that reported by Huang et al. (12). In contrast to Huang et al.’s review (12), where CEUS was used for diagnosing IPN based on histological specimens or the clinical diagnosis of symptomatic plaques, our study focused on detecting vulnerable plaques using CEUS with histologic confirmation. The relevant evidence suggests that neovascularization is a prominent feature of vulnerable plaques (37), originating from the vasa vasorum (VV) network in the outer adventitia, which is simply structured and exhibits high permeability with increased VV density preceding intima thickening and endothelial dysfunction (38). The outer adventitia VV not only contributes to IPN but also serves as a pathway for inflammatory cells to infiltrate the plaque, directly exacerbating its vulnerability. Vascular endothelial growth factor (VEGF) is responsible for angiogenesis, vascular permeability, and endothelial maintenance (39). Both animal and human studies have reported a higher expression of VEGF-positive microvessels in vulnerable plaques compared to stable ones, with these markers showing a positive linear correlation with plaque enhancement on CEUS (19,40). In addition to IPN, plaques with complex features such as prominent echolucency, ulceration, and intraplaque motion are closely associated with ischemic symptoms. Comped to conventional ultrasound (CUS), CEUS can provide clearer visualization of the plaque’s boundaries. Three (17,18,20) out of the nine CEUS studies focused on identifying IPN within the plaque and also assessed plaque ulceration or morphological changes.
Sensitivity analysis revealed that the study conducted by D’Oria et al. (19) was the main factor contributing to the heterogeneity among the included CEUS studies. This discrepancy could be attributed to the variation in participant selection, as D’Oria et al. focused solely on patients with carotid stenosis over 70% who were asymptomatic, while the other studies included both symptomatic and asymptomatic individuals. Nevertheless, the authors demonstrated that there was no significant difference in plaque enhancement between histologically proven vulnerable plaque [American Heart Association (AHA) class VI] and stable plaque (AHA class IV/V). This finding does not diminish the significance of CEUS in detecting IPN.
Diagnostic performance of MRI
According to the available data, IPH is the most extensively documented independent risk factor for the recurrence of ipsilateral ischemia or transient ischemic attack in patients with carotid stenosis ≥50%, as indicated by carotid plaque on MRI (6,41). Zhou et al. (11) performed a meta-analysis to determine the pooled diagnostic accuracy of HR-MRI in detecting IPH and compared to our results, found a comparable sensitivity (0.87 vs. 0.88) but higher specificity (0.92 vs. 0.89). Our study aimed to incorporate all vulnerable plaque components that could be detected by HR-MRI. Within the MRI studies analyzed, seven focused on detecting IPH (24,25,29-32,34) and three on classifying LRNCs (10,26,33). The relationship between plaque composition and cardiovascular events remains a topic of ongoing debate. Longitudinal research over 4 years used serial MRI observed dramatic changes in plaque characteristics, with an IPH and LRNC incidence of 18.5% and 39.6%, respectively (42). Although one study found no association between IPH and symptomatic status (36), it did report a slight correlation between IPH and adverse cardiovascular events. Conversely, LRNC content was found to be significantly higher in systematic plaques (10) and linked to a poor prognosis (43). Notably, a clear relationship exists between IPH, necrotic core expansion, and plaque vulnerability. Additionally, patients undergoing lipid-lowering therapy show increased lipid content in plaques with IPH and decreased content in those without IPH (44), indicating that IPH alone does not encompass all vulnerable or symptomatic plaques.
Implications for clinical practice
Although CEUS and HR-MRI evaluate distinct aspects of vulnerable plaque composition, their combined used can enhance the precision in symptomatic plaque diagnosis, outperforming magnetization-prepared rapid acquisition with gradient echo alone (AUC 0.79 vs. 0.58) (34). According to the Plaque–Reporting and Data System (45), which is based on gray-scale and color Doppler ultrasound, computed tomography angiography, and HR-MRI findings rather than CEUS findings, IPH, IPN, LRNC, and ulceration are key parameters of vulnerable plaques, although IPN has been incorporated as an ancillary feature (37). Pathologically, there is a close relationship between IPH, IPN, and LRNC. The presence of IPH without IPN is rare; nonetheless, extensive IPN can exist without IPH and is still related to plaque vulnerability (34). IPN plays a key role in plaque progression, as fragile neovessels are prone to bleeding. When driven by microenvironmental alternations or inflammatory factors, rupture of IPN leads to the emergence of IPH, with the latter resulting in enlargement of the LRNC and consequently a poor prognosis. In general, CEUS is performed with CUS and color Doppler ultrasound, both of which are cost-effective and convenient for follow-up, enabling the assessment of plaque status and luminal stenosis through gray-scale scoring and flow velocity measurements. Meanwhile, chronic IPH, characterized by hypointensity in all contrast weightings on MRI, can be mistaken for calcification, leading to FNs (30). Although CUS can easily identify calcification, pseudoenhancement, an artifact commonly seen in the far wall of the carotid artery, can mimic contrast enhancement on CEUS. Therefore, HR-MRI and CEUS can complement one another, each capable of detecting different plaque components with their own set of benefits and limitations. The most appropriate examination strategy for identifying susceptible plaques in clinical practice should be determined according to the patient’s particular condition and the resources of the healthcare facility.
It is worth noting that the imaging characteristics of the plaques were contrasted with pathologic findings in all studies to confirm if these plaques are vulnerable; however, truly unstable plaques are associated with the occurrence of a clinical event (e.g., transient ischemic attack or stroke) (46), and current imaging assessments of plaque vulnerability only indicate morphological vulnerability. Therefore, follow-up of clinical outcomes is necessary to further determine the true clinical value of both modalities in the assessment of plaque instability. Furthermore, the development and model construction of artificial intelligence algorithms based on CEUS and MRI have shown great potential for application in plaque classification and segmentation (47). In the future, the innovation of artificial intelligence algorithms through the combination of these two modalities may have the potential to facilitate the identification of plaques morphologically and via microenvironmental changes.
Limitations
This study involved several limitations that should be addressed. First, the comparison of diagnostic performance between CEUS and HR-MRI in evaluating vulnerable carotid plaques was limited by the inclusion of only two paired studies in this review. Most CEUS studies focused on IPN detection and morphological changes, while many MRI studies focused on IPH and LRNCs. Therefore, future paired trials targeting the same plaque component may prove valuable for assessing and comparing the diagnostic efficacy of these two modalities. Second, CEUS lacks a uniform qualitative analysis and set of visual grading scale criteria. Data were extracted from a 2×2 table for analysis, and conducting subgroup analysis for various grade scales is challenging. Additionally, unstable plaques are more likely to be found in patients undergoing carotid endarterectomy for relevant symptomatic stenosis. It is worth noting that some studies categorized patients into symptomatic and asymptomatic groups, which hindered subgroup analyses based on symptomatic or asymptomatic cases. Furthermore, a limited number of studies prevented us from conducting a subgroup analysis of the variable scanning sequences in HR-MRI studies.
ConclusionsOther Section
Both CEUS and HR-MRI are valuable noninvasive diagnostic methods for identifying pathologically proven vulnerable carotid artery plaques and have comparable diagnostic performance. CEUS is more capable of detecting IPN and ulceration, whereas HR-MRI is better suited to classifying IPH and LRNC. CEUS may serve as a potential alternative imaging tool to HR-MRI in assessing carotid plaque vulnerability under certain conditions. However, the published results, sample sizes, and studies incorporated were highly restrictive, and the interstudy heterogeneity was substantial. Further research on CEUS requires the implementation of standardized protocols for qualitative analysis to enhance the reliability and repeatability of results.
AcknowledgmentsOther Section
Funding: This work was supported by
FootnoteOther Section
Reporting Checklist: The authors have completed the PRISMA-DTA reporting checklist. Available at https://qims.amegroups.com/article/view/10.21037/qims-24-540/rc
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-24-540/coif). The authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
ReferencesOther Section
Burkart KG, Brauer M, Aravkin AY, Godwin WW, Hay SI, He J, Iannucci VC, Larson SL, Lim SS, Liu J, Murray CJL, Zheng P, Zhou M, Stanaway JD. Estimating the cause-specific relative risks of non-optimal temperature on daily mortality: a two-part modelling approach applied to the Global Burden of Disease Study. Lancet 2021;398:685-97. [Crossref] [PubMed]
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021;20:795-820. [Crossref] [PubMed]
Zhang R, Liu H, Pu L, Zhao T, Zhang S, Han K, Han L. Global Burden of Ischemic Stroke in Young Adults in 204 Countries and Territories. Neurology 2023;100:e422-34. [Crossref] [PubMed]
Piechocki M, Przewłocki T, Pieniążek P, Trystuła M, Podolec J, Kabłak-Ziembicka A. A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients-A Review: Part I-Epidemiology, Risk Factors, and Atherosclerosis-Related Diversities in Elderly Patients. J Clin Med 2024; [Crossref] [PubMed]
Fabiani I, Palombo C, Caramella D, Nilsson J, De Caterina R. Imaging of the vulnerable carotid plaque: Role of imaging techniques and a research agenda. Neurology 2020;94:922-32. [Crossref] [PubMed]
Bos D, Arshi B, van den Bouwhuijsen QJA, Ikram MK, Selwaness M, Vernooij MW, Kavousi M, van der Lugt A. Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary Events. J Am Coll Cardiol 2021;77:1426-35. [Crossref] [PubMed]
Cui L, Xing Y, Wang L, Chen H, Chen Y. Intraplaque neovascularisation is associated with ischaemic events after carotid artery stenting: an observational prospective study. Ther Adv Neurol Disord 2023;16:17562864221141133. [Crossref] [PubMed]
Hou C, Liu XY, Du Y, Cheng LG, Liu LP, Nie F, Zhang W, He W. Radiomics in Carotid Plaque: A Systematic Review and Radiomics Quality Score Assessment. Ultrasound Med Biol 2023;49:2437-45. [Crossref] [PubMed]
Hou C, Li S, Zhang L, Zhang W, He W. The differences between carotid web and carotid web with plaque: based on multimodal ultrasonic and clinical characteristics. Insights Imaging 2024;15:78. [Crossref] [PubMed]
Chai JT, Biasiolli L, Li L, Alkhalil M, Galassi F, Darby C, Halliday AW, Hands L, Magee T, Perkins J, Sideso E, Handa A, Jezzard P, Robson MD, Choudhury RP. Quantification of Lipid-Rich Core in Carotid Atherosclerosis Using Magnetic Resonance T(2) Mapping: Relation to Clinical Presentation. JACC Cardiovasc Imaging 2017;10:747-56. [Crossref] [PubMed]
Zhou T, Jia S, Wang X, Wang B, Wang Z, Wu T, Li Y, Chen Y, Yang C, Li Q, Yang Z, Li M, Sun G. Diagnostic performance of MRI for detecting intraplaque hemorrhage in the carotid arteries: a meta-analysis. Eur Radiol 2019;29:5129-38. [Crossref] [PubMed]
Huang R, Abdelmoneim SS, Ball CA, Nhola LF, Farrell AM, Feinstein S, Mulvagh SL. Detection of Carotid Atherosclerotic Plaque Neovascularization Using Contrast Enhanced Ultrasound: A Systematic Review and Meta-Analysis of Diagnostic Accuracy Studies. J Am Soc Echocardiogr 2016;29:491-502. [Crossref] [PubMed]
Li Q, Cai M, Wang H, Chen L. Diagnostic Performance of Contrast-Enhanced Ultrasound and High-Resolution Magnetic Resonance Imaging for Carotid Atherosclerotic Plaques: A Systematic Review and Meta-Analysis. J Ultrasound Med 2023;42:739-49. [Crossref] [PubMed]
McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PMPRISMA-DTA Group. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA 2018;319:388-96. [Crossref] [PubMed]
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36. [Crossref] [PubMed]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. [Crossref] [PubMed]
Fresilli D, Di Leo N, Martinelli O, Di Marzo L, Pacini P, Dolcetti V, Del Gaudio G, Canni F, Ricci LI, De Vito C, Caiazzo C, Carletti R, Di Gioia C, Carbone I, Feinstein SB, Catalano C, Cantisani V. 3D-Arterial analysis software and CEUS in the assessment of severity and vulnerability of carotid atherosclerotic plaque: a comparison with CTA and histopathology. Radiol Med 2022;127:1254-69. [Crossref] [PubMed]
Huang S, Wu X, Zhang L, Wu J, He Y, Lai M, Xu J, Li Z. Assessment of Carotid Plaque Stability Using Contrast-Enhanced Ultrasound and Its Correlation With the Expression of CD147 and MMP-9 in the Plaque. Front Comput Neurosci 2021;15:778946. [Crossref] [PubMed]
D'Oria M, Chiarandini S, Pipitone MD, Fisicaro M, Calvagna C, Bussani R, Rotelli A, Ziani B. Contrast Enhanced Ultrasound (CEUS) Is Not Able to Identify Vulnerable Plaques in Asymptomatic Carotid Atherosclerotic Disease. Eur J Vasc Endovasc Surg 2018;56:632-42. [Crossref] [PubMed]
Lyu Q, Tian X, Ding Y, Yan Y, Huang Y, Zhou P, Hui P. Evaluation of Carotid Plaque Rupture and Neovascularization by Contrast-Enhanced Ultrasound Imaging: an Exploratory Study Based on Histopathology. Transl Stroke Res 2021;12:49-56. [Crossref] [PubMed]
Di Leo N, Venturini L, de Soccio V, Forte V, Lucchetti P, Cerone G, Alagna G, Caratozzolo M, Messineo D, Di Gioia C, Di Marzo L, Fresilli D, De Vito C, Pugliese G, Cantisani V, D'Ambrosio F. Multiparametric ultrasound evaluation with CEUS and shear wave elastography for carotid plaque risk stratification. J Ultrasound 2018;21:293-300. [Crossref] [PubMed]
Iezzi R, Petrone G, Ferrante A, Lauriola L, Vincenzoni C, la Torre MF, Snider F, Rindi G, Bonomo L. The role of contrast-enhanced ultrasound (CEUS) in visualizing atherosclerotic carotid plaque vulnerability: which injection protocol? Which scanning technique? Eur J Radiol 2015;84:865-71. [Crossref] [PubMed]
Uchihara Y, Saito K, Motoyama R, Ishibashi-Ueda H, Yamaguchi E, Hatakeyama K, Tanaka A, Kataoka H, Iihara K, Sugie K, Koga M, Toyoda K, Nagatsuka K, Ihara M. Neovascularization From the Carotid Artery Lumen Into the Carotid Plaque Confirmed by Contrast-Enhanced Ultrasound and Histology. Ultrasound Med Biol 2023;49:1798-803. [Crossref] [PubMed]
Ota H, Yarnykh VL, Ferguson MS, Underhill HR, Demarco JK, Zhu DC, Oikawa M, Dong L, Zhao X, Collar A, Hatsukami TS, Yuan C. Carotid intraplaque hemorrhage imaging at 3.0-T MR imaging: comparison of the diagnostic performance of three T1-weighted sequences. Radiology 2010;254:551-63. [Crossref] [PubMed]
Narumi S, Sasaki M, Natori T, Yamaguchi Oura M, Ogasawara K, Kobayashi M, Sato Y, Ogasawara Y, Hitomi J, Terayama Y. Carotid plaque characterization using 3D T1-weighted MR imaging with histopathologic validation: a comparison with 2D technique. AJNR Am J Neuroradiol 2015;36:751-6. [Crossref] [PubMed]
Puppini G, Furlan F, Cirota N, Veraldi G, Piubello Q, Montemezzi S, Gortenuti G. Characterisation of carotid atherosclerotic plaque: comparison between magnetic resonance imaging and histology. Radiol Med 2006;111:921-30. [Crossref] [PubMed]
Moody AR, Murphy RE, Morgan PS, Martel AL, Delay GS, Allder S, MacSweeney ST, Tennant WG, Gladman J, Lowe J, Hunt BJ. Characterization of complicated carotid plaque with magnetic resonance direct thrombus imaging in patients with cerebral ischemia. Circulation 2003;107:3047-52. [Crossref] [PubMed]
Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 2002;106:1368-73. [Crossref] [PubMed]
Kampschulte A, Ferguson MS, Kerwin WS, Polissar NL, Chu B, Saam T, Hatsukami TS, Yuan C. Differentiation of intraplaque versus juxtaluminal hemorrhage/thrombus in advanced human carotid atherosclerotic lesions by in vivo magnetic resonance imaging. Circulation 2004;110:3239-44. [Crossref] [PubMed]
Chu B, Kampschulte A, Ferguson MS, Kerwin WS, Yarnykh VL, O'Brien KD, Polissar NL, Hatsukami TS, Yuan C. Hemorrhage in the atherosclerotic carotid plaque: a high-resolution MRI study. Stroke 2004;35:1079-84. [Crossref] [PubMed]
Qiao Y, Etesami M, Malhotra S, Astor BC, Virmani R, Kolodgie FD, Trout HH 3rd, Wasserman BA. Identification of intraplaque hemorrhage on MR angiography images: a comparison of contrast-enhanced mask and time-of-flight techniques. AJNR Am J Neuroradiol 2011;32:454-9. [Crossref] [PubMed]
Cappendijk VC, Cleutjens KB, Heeneman S, Schurink GW, Welten RJ, Kessels AG, van Suylen RJ, Daemen MJ, van Engelshoven JM, Kooi ME. In vivo detection of hemorrhage in human atherosclerotic plaques with magnetic resonance imaging. J Magn Reson Imaging 2004;20:105-10. [Crossref] [PubMed]
Tapis P, El-Koussy M, Hewer E, Mono ML, Reinert M. Plaque vulnerability in patients with high- and moderate-grade carotid stenosis - comparison of plaque features on MRI with histopathological findings. Swiss Med Wkly 2020;150:w20174. [Crossref] [PubMed]
Motoyama R, Saito K, Tonomura S, Ishibashi-Ueda H, Yamagami H, Kataoka H, Morita Y, Uchihara Y, Iihara K, Takahashi JC, Sugie K, Toyoda K, Nagatsuka K. Utility of Complementary Magnetic Resonance Plaque Imaging and Contrast-Enhanced Ultrasound to Detect Carotid Vulnerable Plaques. J Am Heart Assoc 2019;8:e011302. [Crossref] [PubMed]
Zhao KQ, Xie X, Yin HF, Zhao JL, Cao ZJ, Yang Y, Jiang C, Zhu RR, Wu WW. Clinical cohort study of imaging evaluation and postoperative pathology of carotid vulnerable plaque. Zhonghua Yi Xue Za Zhi 2018;98:2424-8. [PubMed]
Di Napoli A, Cheng SF, Gregson J, Atkinson D, Markus JE, Richards T, Brown MM, Sokolska M, Jäger HR. Arterial Spin Labeling MRI in Carotid Stenosis: Arterial Transit Artifacts May Predict Symptoms. Radiology 2020;297:652-60. [Crossref] [PubMed]
Hou C, Li MX, He W. Carotid Plaque-RADS: A Novel Stroke Risk Classification System. JACC Cardiovasc Imaging 2024;17:226. [Crossref] [PubMed]
Mulligan-Kehoe MJ. The vasa vasorum in diseased and nondiseased arteries. Am J Physiol Heart Circ Physiol 2010;298:H295-305. [Crossref] [PubMed]
Zhu F, Yuan S, Li J, Mou Y, Hu Z, Wang X, Sun X, Ding J, Zheng Z. Cilengitide Inhibits Neovascularization in a Rabbit Abdominal Aortic Plaque Model by Impairing the VEGF Signaling. Biomed Res Int 2021;2021:5954757. [Crossref] [PubMed]
Wu Y, Li X, Wang Z, Zhang S, Feng Y, Sun L. Real-time Elastography and Contrast-Enhanced Ultrasound for Evaluating Adventitia in the Early Diagnosis of Vulnerable Plaques: an Exploratory Study Based on Histopathology. Transl Stroke Res 2024;15:545-55. [Crossref] [PubMed]
van Dam-Nolen DHK, Truijman MTB, van der Kolk AG, Liem MI, Schreuder FHBM, Boersma E, Daemen MJAP, Mess WH, van Oostenbrugge RJ, van der Steen AFW, Bos D, Koudstaal PJ, Nederkoorn PJ, Hendrikse J, van der Lugt A, Kooi MEPARISK Study Group. Carotid Plaque Characteristics Predict Recurrent Ischemic Stroke and TIA: The PARISK (Plaque At RISK) Study. JACC Cardiovasc Imaging 2022;15:1715-26. [Crossref] [PubMed]
Pletsch-Borba L, Selwaness M, van der Lugt A, Hofman A, Franco OH, Vernooij MW. Change in Carotid Plaque Components: A 4-Year Follow-Up Study With Serial MR Imaging. JACC Cardiovasc Imaging 2018;11:184-92. [Crossref] [PubMed]
Sun J, Zhao XQ, Balu N, Neradilek MB, Isquith DA, Yamada K, Cantón G, Crouse JR 3rd, Anderson TJ, Huston J 3rd, O'Brien K, Hippe DS, Polissar NL, Yuan C, Hatsukami TS. Carotid Plaque Lipid Content and Fibrous Cap Status Predict Systemic CV Outcomes: The MRI Substudy in AIM-HIGH. JACC Cardiovasc Imaging 2017;10:241-9. [Crossref] [PubMed]
Zhao XQ, Sun J, Hippe DS, Isquith DA, Canton G, Yamada K, Balu N, Crouse JR 3rd, Anderson TJ, Huston J 3rd, O'Brien KD, Hatsukami TS, Yuan CAIM-HIGH Carotid MRI Substudy Investigators. Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH. Circ Cardiovasc Imaging 2022;15:e014229. [Crossref] [PubMed]
Saba L, Cau R, Murgia A, Nicolaides AN, Wintermark M, Castillo M, et al. Carotid Plaque-RADS: A Novel Stroke Risk Classification System. JACC Cardiovasc Imaging 2024;17:62-75. [Crossref] [PubMed]
Jiang C, Meng Q, Zhao K, Zhao H, Zheng Z, Wu W, Zhao X. Vulnerable carotid plaque characteristics on magnetic resonance vessel wall imaging: potential predictors for hemodynamic instability during carotid artery stenting. Quant Imaging Med Surg 2023;13:3441-50. [Crossref] [PubMed]
Han N, Ma Y, Li Y, Zheng Y, Wu C, Gan T, Li M, Ma L, Zhang J. Imaging and Hemodynamic Characteristics of Vulnerable Carotid Plaques and Artificial Intelligence Applications in Plaque Classification and Segmentation. Brain Sci 2023;13:143. [Crossref] [PubMed]
Cite this article as: Hou C, Xuan JQ, Zhao L, Li MX, He W, Liu H. Comparison of the diagnostic performance of contrast-enhanced ultrasound and high-resolution magnetic resonance imaging in the evaluation of histologically defined vulnerable carotid plaque: a systematic review and meta-analysis. Quant Imaging Med Surg 2024;14(8):5814-5830. doi: 10.21037/qims-24-540
感谢QIMS杂志授权转载!
原文链接:
https://qims.amegroups.org/article/view/126906/html
About the Journal
Quantitative Imaging in Medicine and Surgery
Aims and Scope
Quantitative Imaging in Medicine and Surgery (QIMS, Quant Imaging Med Surg, Print ISSN 2223-4292; Online ISSN 2223-4306) publishes peer-reviewed original reports and reviews in medical imaging, including X-ray, ultrasound, computed tomography, magnetic resonance imaging and spectroscopy, nuclear medicine and related modalities, and their application in medicine and surgery. While focus is on clinical investigations, papers on medical physics, image processing, or biological studies which have apparent clinical relevance are also published. This journal encourages authors to look at the medical images from a quantitative angle. This journal also publishes important topics on imaging-based epidemiology, and debates on research methodology, medical ethics, and medical training. Descriptive radiological studies of high clinical importance are published as well.
QIMS is an open-access, international peer-reviewed journal, published by AME Publishing Company. It is published quarterly (Dec. 2011- Dec. 2012), bimonthly (Feb. 2013 - Feb 2018), monthly (Mar. 2018 - ) and openly distributed worldwide.
QIMS is indexed in PubMed/PubMed Central, Scopus, Web of Science [Science Citation Index Expanded (SCIE)]. The latest impact factor is: 2.9.
Indexing
Quantitative Imaging in Medicine and Surgery is indexed and covered by
Web of Science [Science Citation Index Expanded (SCIE)]
PubMed
PubMed Central (PMC)
Google Scholar
Scopus
Information for Authors
QIMS is a member of Committee on Publication Ethics (COPE) and it follows the Committee on Publication Ethics (COPE)'s guidelines and the ICMJE recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journal.
Manuscripts submitted must be the original work of the author(s) and must not be published previously or under consideration for publication elsewhere.
Manuscripts Turnaround Time
First Editorial Decision: 3-5 days
Peer review: 1-2 months
Revision time: 2-4 weeks
Publication Ahead of Print: within 1 month after being accepted
Formal publication: within 1-3 months after being accepted. Original Articles are listed as priority.
QIMS’s position on case reports and review articles.
QIMS welcomes case reports where quantitative imaging played a role for diagnosis and/or treatment; also welcome first time realization (in animals or in human subjects) of a new imaging technique. These case reports are usually written a concise and short letter format (see <https://qims.amegroups.com/>) for example. Case reports of particular clinical importance are also published in a longer format; for these cases we expect important pathophysiological, diagnostic, therapeutic implications. We do not publish case report only because of the rarity of the cases. Note, although we believer reporting case materials is important for the advancement of medicine. The space reserved for case report remains limited for each issue. The decision to publish or not publish a case material submission can sometimes depend on the available space of the journal.
QIMS welcomes reviews and comments on published papers. Review papers should contain authors’ analytical appraisal of published papers and personal viewpoints, instead of a mere aggregation of published abstracts.
We expect review papers are in three forms, 1) expert reviews, usually published in editorial format, provide authors’ own insights and perspective; 2) systematic review; 3) educational reviews, including pictorial reviews. Systematic reviews (maybe narrative in writing but critical in nature) are particularly welcomed.
Publication Schedule
Published quarterly from Dec. 2011 to Dec. 2012 and bimonthly from Feb. 2013 to Feb 2018, QIMS now follows a monthly publication model.
Open Access Statement
This journal is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for all to read, download, copy and distribute as defined by the applied license.
Free access and usage
Permitted third party reuse is defined by the CC BY-NC-ND 4.0 license. This license allows users to copy and distribute the article, provided:
this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way.
the user gives appropriate credit (with a link to the formal publication through the relevant DOI) and provides a link to the license but not in an any way implying that the licensor is endorsing the user or the use of the work.
no derivatives including remix, transform, or build upon the material was allowed for distribution.
The full details of the license are available at https://creativecommons.org/licenses/by-nc-nd/4.0/
Copyright
For open access publishing, this journal uses an exclusive licensing agreement. Authors will transfer copyright to QIMS, but will have the right to share their article in the same way permitted to third parties under the relevant user license, as well as certain scholarly usage rights.
For any inquiry/special circumstance on the copyright, commercial usage or adaptation of QIMS articles, please contact: permissions@amegroups.com
For reprint order, please contact: sales@amegroups.com
Support for Authors to Comply with Funding Body Mandates
We work with authors of research articles supported by funding bodies with open access mandates to ensure that authors can meet their funders’ requirements for public access to research results.
In addition, we offer further support for authors who are required to comply with funding body mandates, including but not limited to:
All articles published open access will be immediately and permanently free for everyone to read, download, copy and distribute. If a specific open access license is needed, please contact the editorial office for confirmation before submission. Example of statements in a published article: https://jgo.amegroups.org/article/view/76355/html.
No copyright is claimed for any work of the U.S. government. Example of statements in published articles: https://actr.amegroups.org/article/view/8875; https://med.amegroups.org/article/view/8358/html.
Editorial Office
Email: qims@amepc.org
Publisher Information
QIMS is published by AME Publishing Company.
Addresses:
Hong Kong branch office: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China.
Singapore branch office: Pico Creative Centre, 20 Kallang Ave #03-08, 339411 Singapore, Singapore.
Updated on July 19, 2024
感谢QIMS授权转载!
观点:王毅翔等——新冠肺炎CT检查的临床意义未定,尽可能避免,武汉/湖北除外!
SCI之窗(005)—杜二珠、王毅翔等:调整X 线焦点投照位置以提高正位胸片对椎体骨质疏松性压缩变形的检出率
王毅翔 等:肝脏弥散加权磁共振ADC及IVIM定量 : 现有的困难及部分解决方法
SCI之窗(006)—王毅翔等:老年华人女性骨质疏松性椎体压缩性骨折的发病率及严重程度远低于欧美人群
SCI之窗(011):对东亚男女性老年人修正1994WHO T-值定义骨质疏松的阈值以使其与东亚人群终生脆性骨折的风险一致
QIMS之窗(006):18F-FDG-PET/CT 在结核病诊断及疗效评估中的价值
QIMS之窗(007):腹壁肿瘤及肿瘤样病变的CT及MRI表现
QIMS之窗(008):结合非强化磁共振血管造影、血流定量及灌注成像评估将发生的再次中风
QIMS之窗(009):颅内动脉瘤的神经影像学:考虑瘤体大小以外的解剖及血流动力学因素
QIMS之窗(010):髓鞘脂的UTE (超短回波时间) 磁共振成像:技术发展及挑战
QIMS之窗(011):新冠患者CT测量得到的肺血管指数及临床预后间的关系
QIMS之窗 (012): 双能CT肺血管造影显示新冠肺炎的微血管病变
QIMS之窗 (013): 胸部平片用于严重新冠病的临床价值
QIMS之窗 (014): 活动性肺结核的几种不典型CT表现及机制
QIMS之窗 (015): 类风湿关节炎患者高分辨率外周定量CT评估掌指关节3维关节间隙宽度的共识方法
QIMS之窗 (016): 骨质疏松症的影像学及骨密度诊断: 中国专家共识(英文版)
QIMS之窗 (017): 新冠肺炎的一种新CT征象: 拱形桥征
QIMS之窗 (018): 老年男性X线骨质疏松性椎体骨折综述:聚焦于男女性别间差异
QIMS之窗 (022): 双能CT区分甲状腺乳头状癌患者小于0.5 cm的转移性和非转移性淋巴结
QIMS之窗 (023): 正位胸片及腹部正位平片上识别骨质疏松性椎体压缩变形: 图文综述
QIMS之窗 (024): 基于人工智能的血管抑制技术应用于肺癌筛查中半实性小结节检测
QIMS之窗 (026): 磁共振成像显示前胫腓韧带损伤与踝关节状态及其肌腱、韧带的关系
QIMS之窗 (027): 腹主动脉瘤的CT测量:非标准化测量的临床后果及多平面重建的重要性
QIMS之窗 (028): 人工智能辅助诊断减少急诊全身CT的胸部病变漏诊
QIMS之窗 (029): 性别各异的肝脏衰老过程与磁共振成像
QIMS之窗 (030): 今天的放射科医生遇到明天的人工智能: 许诺、陷阱和无限的潜力
QIMS之窗 (032): 通过多模态融合成像三维定量评估心肌梗死: 方法学、验证和初步临床应用
QIMS之窗 (033): 门脉高压的侧枝循环:解剖及临床相关性
QIMS之窗 (034):医学图像分析应用中计算机视觉和人工智能的新进展
QIMS之窗 (035):大动脉壁的应力分布对动脉粥样硬化的影响
QIMS之窗 (036): 人工智能计算机辅助诊断系统评估肺癌、转移瘤和良性病变的预测准确性
QIMS之窗 (037):4D 血流 MRI 在心血管疾病的临床应用:现状和未来展望
QIMS之窗 (038): 含碘造影剂的交叉反应:我们需要关注吗?
QIMS之窗 (039): 全脑分析显示正常中青年深部灰质和大脑皮层年龄相关性磁敏感率变化
QIMS之窗 (040): 颈动脉支架术治疗后新发缺血性脑病灶与颈动脉钙化环壁分布程度相关
QIMS之窗 (041): 先进脑磁共振技术转化为临床实践:多模态磁共振在传统临床条件下区分痴呆亚型
QIMS之窗 (042): 3,557 名感染 COVID-19 儿童的CT扫描表现: 系统性综述
QIMS之窗 (043): 肩关节不稳影像学图文综述QIMS之窗 (044): 多排计算机断层扫描评估肝门部胆管癌血管受累
QIMS之窗 (045): 多发性骨髓瘤患者肿瘤负荷的全身磁共振成像定量评估: 与预后生物标志物的相关性
QIMS之窗 (046): 虚拟或真实: 肾上腺肿瘤的活体样电影模式重建
QIMS之窗 (047): 血池和肝脏PET 标准化摄取值的年龄相关变化: 对 2526 名患者长达十年的回顾性研究结果
QIMS之窗 (048): 辨认骨质疏松性椎体终板及皮质骨折: 图文综述
QIMS之窗 (049): 经皮冠状动脉介入治疗后有症状患者心肌灌注受损的临床和影像预测因素:动态CT心肌灌注成像的表现
QIMS之窗 (050): 定量磁共振 神经成像用于评估周围神经和神经丛损伤: 图文综述
QIMS之窗 (051): 儿童颈部良恶性肿块的影像学诊断: 图文综述
QIMS之窗 (052): CT肺结节半自动分割 的常规方法和深度学习方法的比较评估
QIMS之窗 (053): 通过ICC评估放射组学特征的可靠性: 系统性综述
QIMS之窗 (054): 550 例小儿脑肿瘤定性 MRI 的诊断准确性:评估计算时代的临床实践
QIMS之窗 (055): 年龄和吸烟对中国健康男性肺血管容积的影响 : 低剂量CT定量测量
QIMS之窗 (056): 通过薄层CT扫描区分肺部部分实性结节的良恶性
QIMS之窗 (057): 不同阶段高血压患者脑白质变化、高血压病程、年龄与脑微出血有关
QIMS之窗 (058): 乳动脉钙化作为动脉粥样硬化性心血管疾病的指标:冠状动脉CT评分系统和颈动脉内中膜厚度的比较分析
QIMS之窗 (059): 老年华人骨质疏松性骨折的发生率不到欧美人群的一半
QIMS之窗 (060): 基于简化时序方案的黑血延时钆增强心脏磁共振成像用于心肌瘢痕检测:检查怀疑冠状动脉疾病患者的单中心经验
QIMS之窗 (061): 弥漫性肝病的 CT 和 MR: 多参数预测建模算法帮助肝实质分类
QIMS之窗 (062): 心脏磁共振评价川崎病患儿心肌综合收缩力: 大型单中心研究
QIMS之窗 (063): 胸腰脊柱骨折的分类: 定量影像学的作用
QIMS之窗 (064): 不规则骨及扁平骨的骨肉瘤: 112例患者的临床及影像学特征
QIMS之窗 (065): “华人脊椎更健康”: MrOS (Hong Kong)和 MsOS(Hong Kong) 研究进展
QIMS之窗 (066): 低球管电压方案CT平描无创诊断肝脂肪
QIMS之窗 (067): 全身磁共振成像在成人淋巴瘤患者分期中的诊断性能—系统综述和荟萃分析
QIMS之窗 (069): 使用放射组学和组合机器学习对帕金森病进展进行纵向聚类分析和预测
QIMS之窗 (070): 直肠内超声和MRI使用直肠系膜浸润深度5mm为截止点对T3直肠癌进行术前亚分类的一致性和存活的意义
QIMS之窗 (071): 肺结节的体积分析:减少基于直径的体积计算和体素计数方法之间的差异
QIMS之窗 (072):深度学习图像重建可降低射线剂量成像的同时保持图像质量:增强腹部CT扫描深度学习重建与混合迭代重建的比较
QIMS之窗 (073): 严重钙化冠状动脉中隐藏的不稳定的斑块
QIMS之窗 (074): 放射组学和混合机器学习对帕金森病进展的纵向聚类分析和预测
QIMS之窗 (075): 冠状动脉慢性完全闭塞病人心血管磁共振成像随访应力分析和晚期钆增强的量化
QIMS之窗 (076): 平扫光谱CT有效原子序数图识别无钙化动脉粥样硬化斑块的临床可行性初步研究
QIMS之窗 (077): 7T磁共振神经影像学: 图文综述QIMS之窗 (078): MRI特征区分结直肠肝转移瘤的组织病理学生长模式
QIMS之窗 (079): 弱监督学习使用弥散加权成像检出急性缺血性中风和出血性梗塞病变的能力
QIMS之窗 (080): 无造影强化光谱CT有效原子序数图识别无钙化动脉粥样硬化斑块:临床可行性初步研究
QIMS之窗 (081): ImageJ定量测量超微血管成像与造影增强超声定量测量对于肝脏转移瘤检查的比较: 初步研究结果
QIMS之窗 (082): 剪切波弹性成像显示: 无论先前抗病毒治疗如何, 慢性戊型肝炎患者肝组织硬度均升高
QIMS之窗 (083): 磁共振与CT在脊柱骨病变中的价值
QIMS之窗 (084): 一种简化评分方案以提高MRI乳房成像报告/数据系统的诊断准确性
QIMS之窗 (085): 晚年抑郁症进展与 MRI 定量磁敏感性测量脑铁沉积的变化
QIMS之窗 (086): 吸烟通过调节黑质纹状体通路中铁沉积与临床症状之间的相互作用对帕金森病起到保护作用
QIMS之窗 (087): 急性肺栓塞后血栓栓塞持续存在的临床和影像学危险因素
QIMS之窗 (088): 在老年女性侧位胸片上自动检出椎体压缩性骨折的软件: Ofeye 1.0
QIMS之窗 (089): 脑血流与脑白质高信号进展之间的关联:一项基于社区成年人的纵向队列研究
QIMS之窗 (090): 基于骨密度诊断老年华人骨质疏松症发病率和定义骨质疏松症的临界T值
QIMS之窗 (091): 臂丛神经磁共振束成像: 循序渐进的步骤
QIMS之窗 (092): 造血病患者通过磁共振模块化报告评估骨髓
QIMS之窗 (093): 使用无造影剂和无触发的弛豫增强血管造影 (REACT) 评估急性缺血性中风的近端颈内动脉狭窄
QIMS之窗 (094): 用于预测自发性脑出血后不良预后和 30 天死亡率的临床-放射组学列线图
QIMS之窗 (095): 深度学习在超声成像识别乳腺导管原位癌和微浸润中的应用
QIMS之窗 (096): 磁共振灌注成像区分胶质瘤复发与假性恶化:系统性综述、荟萃分析及荟萃回归
QIMS之窗 (097): 锥形束 CT 引导微波消融治疗肝穹窿下肝细胞癌:回顾性病例对照研究
QIMS之窗 (098): 阿尔茨海默病患者皮质铁积累与认知和脑萎缩的关系
QIMS之窗 (099): 放射组学机器学习模型使用多样性的MRI数据集检出有临床意义前列腺癌的性能不均一性
QIMS之窗 (100): 一种机器学习方法结合多个磁共振弥散散模型来区分低级别和高级别成人胶质瘤
QIMS之窗 (101): MRPD脂肪分数 (MRI-PDFF)、MRS 和两种组织病理学方法(AI与病理医生)量化脂肪肝
QIMS之窗 (102): 占位性心脏病患者的诊断和生存分析:一项为期10年的单中心回顾性研究
QIMS之窗 (103): Ferumoxytol增强4DMR多相稳态成像在先心病中的应用:2D和3D软件平台评估心室容积和功能
QIMS之窗 (104): 磁共振弹性成像对肝细胞癌肝切除术后肝再生的术前评价
QIMS之窗 (105): 使用定量时间-强度曲线比较炎症性甲状腺结节和甲状腺乳头状癌的超声造影特征:倾向评分匹配分析
QIMS之窗 (106): 口服泡腾剂改善磁共振胰胆管造影 (MRCP)
QIMS之窗 (107): 钆磁共振成像造影剂引起的弛豫率改变显示阿尔茨海默病患者微血管形态变化
QIMS之窗 (108): 轻链心肌淀粉样变性患者左心室心肌做功指数和短期预后:一项回顾性队列研究
QIMS之窗 (109): 基于MR放射组学的机器学习对高级别胶质瘤患者疾病进展的预测价值
QIMS之窗 (110): 高分辨率T2加权MRI与组织病理学集合分析显示其在食管癌分期中的意义
QIMS之窗 (111): 使用多参数磁共振成像和波谱预测放射治疗后前列腺癌的复发: 评估治疗前成像的预后因素
QIMS之窗 (112):双层能谱探测器CT参数提高肺腺癌分级诊断效率
QIMS之窗 (113): 弥散加权T2图谱在预测头颈部鳞状细胞癌患者组织学肿瘤分级中的应用
QIMS之窗 (114): 老年女性椎体高度下降不到 20% 的骨质疏松样椎体骨折与进一步椎体骨折风险增加有关:18年随访结果
QIMS之窗 (115): 膝关节周围巨细胞瘤和软骨母细胞瘤的影像学:99例回顾性分析
QIMS之窗 (116): 胸部CT显示分枝杆菌感染空洞:临床意义和基于深度学习的量化自动检测
QIMS之窗 (117): 基于人工智能的甲状腺结节筛查自动诊断系统的统计优化策略评估和临床评价
QIMS之窗 (118): 基于四维血流磁共振成像的弯曲大脑中动脉壁切应力的分布和区域变化
QIMS之窗 (119): 我们最近关于老年男性和女性流行性骨质疏松性椎体骨折X线诊断的循证工作总结
QIMS之窗 (120): 许莫氏结节与流行性骨质疏松性椎体骨折和低骨密度有关:一项基于老年男性和女性社区人群的胸椎MRI研究
QIMS之窗 (121): 心肌梗死后射血分数保留的心力衰竭患者: 心肌磁共振(MR)组织追踪研究
QIMS之窗 (122): 使用 人工智能辅助压缩传感心脏黑血 T2 加权成像:患者队列研究
QIMS之窗 (123): 整合式18F-FDG PET/MR全身扫描机局部增强扫描在胰腺腺癌术前分期及可切除性评估中的价值
QIMS之窗 (124): 放射组学预测胶质瘤异柠檬酸 脱氢酶基因突变的多中心研究
QIMS之窗 (125): CT与组织病理学对评估冠状动脉钙化的敏感性和相关性的比较
QIMS之窗 (126): 磁敏感加权成像鉴别良恶性门静脉血栓的价值
QIMS之窗 (127): 乳腺癌的超声诊断深度学习模型:超声与临床因素的整合
QIMS之窗 (128): 钆塞酸增强磁共振成像肝胆期成像的优化:叙述性综述
QIMS之窗 (130): 退行性颈椎病患者检出偶发甲状腺结节:一项回顾性 MRI 研究
QIMS之窗 (131):主要由发育原因引起的许莫氏结节和主要由后天原因引起的许莫氏结节:两个相关但不同的表现
QIMS之窗 (132):肱骨头囊性病变: 磁共振成像图文综述
QIMS之窗 (133):高分辨率小视场弥散加权磁共振成像在宫颈癌诊断中的应用
QIMS之窗 (135):深度学习辅助放射平片对膝关节关节炎分级:多角度X线片与先验知识的作用
QIMS之窗 (136): Angio-CT 影像学生物标志预测肝细胞癌经动脉化疗栓塞的疗效
QIMS之窗 (137):术前低放射剂量CT引导下肺结节定位
QIMS之窗 (138):超声造影在乳腺癌患者前哨淋巴结评估和标测中的应用
QIMS之窗 (140):反转恢复超短回波时间 (IR-UTE) 磁共振对脑白质病变的临床评估
QIMS之窗 (141): 层厚对基于深度学习的冠状动脉钙自动评分软件性能的影响
QIMS之窗 (142):支气管内超声弹性成像鉴别肺门纵隔淋巴结良恶性:回顾性研究
QIMS之窗 (143):高血压和肥胖对左心房时相功能的交互作用:三维超声心动图研究
QIMS之窗 (144):超声造影在乳腺癌患者前哨淋巴结评估和标测中的应用
QIMS之窗 (145):基于K-means层级体素聚类的快速高信噪比CEST量化方法
QIMS之窗 (146):常规临床多排CT扫描自动分割机会性评估椎体骨密度和纹理特征的长期可重复性
QIMS之窗 (147):基于人工智能的CT 扫描特征直方图分析预测毛玻璃结节的侵袭性
QIMS之窗 (148):基于心脏CTA图像与超声心动图的深度监督8层residual U-Net计算左心室射血分数
QIMS之窗 (149): 高度实性成分对早期实性肺腺癌的预后影响
QIMS之窗 (150):只在磁共振发现的可疑乳腺病变: 定量表观弥散系数有额外的临床价值吗 ?
QIMS之窗 (151): 人工智能与放射科医生在CT图像骨折诊断准确性方面的比较: 多维度、多部位分析
QIMS之窗 (152): 超声剪切波速检测人群晚期肝纤维化
QIMS之窗 (153):使用Gd-EOB-DTPA增强MR结合血清标志物在乙肝病毒高危患者中区分肿块型肝内胆管癌和非典型HCC
QIMS之窗 (154):术前超声预测甲状腺癌患者喉返神经侵犯
QIMS之窗 (155): T2 弛豫时间对 MRI 表观扩散系数 (ADC) 量化的影响及其潜在的临床意义
QIMS之窗 (156): 成人血液系统恶性肿瘤的急性病变神经放射学:图文综述
QIMS之窗 (157): 老年休闲运动最常见的15种肌肉骨骼损伤: 图文综述
QIMS之窗 (158): T2弛豫时间与磁共振成像表观弥散系数 (ADC) 之间的三相关系
QIMS之窗 (159): T2弛豫时间在解释肌肉骨骼结构MRI表观弥散系数(ADC)的意义
QIMS之窗 (160): 膝骨关节炎的影像学:多模式诊断方法综述
QIMS之窗 (161): 超高场 7T MRI 在帕金森病中准备用于临床了吗?—叙述性综述
QIMS之窗 (162): 碘造影剂在CT结构化RADS中的作用——叙述性综述
QIMS之窗 (163): 医学图像分割中的Transformers: 叙述性综述
QIMS之窗 (164): 肝癌相对于肝组织的长T2导致常规IVIM成像肝癌灌注分数被低估
QIMS之窗 (165): 基于深度学习的多模态肿瘤分割方法: 叙述性综述
QIMS之窗 (167): 基于双能CT的新型生物标志物用于结直肠癌手术后极早期远处转移的风险分层
QIMS之窗 (168): ST段抬高型心肌梗死患者心肌内出血的心脏磁共振成像检测:磁敏感加权成像与T1/T2像素图技术的比较
QIMS之窗 (169): TW3人工智能骨龄评估系统的验证:一项前瞻性、多中心、确认性研究
QIMS之窗 (170): 开发和验证深度学习模型用于髋关节前后位和侧位X线片检测无移位的股骨颈骨折
QIMS之窗 (171): 开滦研究中眼球血管宽度与认知能力下降和脑小血管病负担的关系
QIMS之窗 (172): 终板炎性矮椎(Endplatitis short vertebrae)
QIMS之窗 (173): DDVD像素图的潜在广泛临床应用
QIMS之窗 (174): 弥散性甲状腺病变中超声低回声特点及原理
QIMS之窗 (175): 不同发育状态及成长时期儿童青少年的手部骨骼特征
QIMS之窗 (176): 不同肌肉测量技术在诊断肌肉减少症中的一致性:系统性综述及荟萃分析
QIMS之窗 (177): 用于冠状动脉狭窄功能评估的冠状动脉树描述和病变评估 (CatLet) 评分:与压力线FFR的比较
QIMS之窗 (178): 使用 Sonazoid 的CEUS LI-RADS诊断肝细胞癌的效果:系统评价和荟萃分析
QIMS之窗 (179): 更多证据支持东亚老年女性骨质疏松症QCT腰椎BMD诊断临界点值应该低于欧裔人
QIMS之窗 (180): 相对于无肿瘤直肠壁,直肠癌的血液灌注更高:通过一种新的影像学生物标志物DDVD进行量化
QIMS之窗 (181): 人工智能在超声图像上解释甲状腺结节的诊断性能:一项多中心回顾性研究
QIMS之窗 (182): 先天许莫氏结节有软骨终板完全覆盖及其在许莫氏结节基于病因学分类的意义
QIMS之窗 (183): 合成磁共振成像在预测乳腺癌前哨淋巴结的额外价值
QIMS之窗 (184): 通过体积倍增时间预测早期肺腺癌生长导致分期改变
QIMS之窗 (185): 对比增强盆腔MRI用于预测粘液性直肠癌的治疗反应
QIMS之窗 (186): 探讨骨质疏松症和骨折风险中椎旁肌肉与骨骼健康之间的相互作用:CT和MRI研究全面文献综述
QIMS之窗 (187): 心动周期对双层计算机断层扫描心肌细胞外体积分数测量的影响
QIMS之窗 (188): 帕金森病和多系统萎缩皮质下铁沉积的定量磁敏感图:临床相关性和诊断意义
QIMS之窗 (189): 0~14岁儿童脑18氟脱氧葡萄糖正电子发射断层扫描正常对照模型的建立及变化规律分析
QIMS之窗 (190): 急性缺血性卒中后早期神经功能恶化的多模态成像评估
QIMS之窗 (192): 良性甲状腺结节的分期:原理和超声征象
QIMS之窗 (193): 独立评估5款人工智能软件检测胸片肺结节的准确性
QIMS之窗 (194): 合成磁共振成像在前列腺癌侵袭性诊断和评估中的价值